FDA Panel Says Ocriplasmin Benefits Outweigh Risks; Recommends Approval Of Ranibizumab

Home
Cataract
Cornea
Glaucoma
Refractive
Retina
Practice Management

Friday, July 27, 2012

Ocular Surgery News

Ocular Surgery News live blogged Thursday's U.S. Food and Drug Administration’s Dermatologic and Ophthalmic Drugs Advisory Committee meeting on ranibizumab and ocriplasmin.

Full Story

All of the following are risk factors for the disorder shown EXCEPT:
1. iris color
2. obesity
3. smoking
4. hypertension
Check The Answer

VISUPLAN 500 Non-Contact Tonometer
The measurement of intraocular pressure ... view product
Volk iNview
iPhone Fundus Camera The Volk iNview ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

FDA Panel Says Ocriplasmin Benefits Outweigh Risks; Recommends Approval Of Ranibizumab

Comments

Quick Quiz

All of the following are risk factors for the disorder shown EXCEPT:

AdGlare RMR Ad

Featured Products

VISUPLAN 500 Non-Contact Tonometer

Volk iNview

Follow OphthalmologyWeb

Write for Us

AdGlare RMR2